Telor Ophthalmic Pharmaceuticals, which has just published its second-quarter and half-year results (pages 6 and 7), has announced that its lead product in development, Xarano (ethacrynate sodium), has performed no better than placebo in Phase III clinical trials.
Xarano is a formulation of ethacrynate which has been under development for reducing or preventing the intraocular pressure spike which is often associated with cataract surgery in patients with elevated IOP. The analysis of the Phase III trial data showed that there was no statistically significant difference between two treatment groups at different doses and the control group in the primary and secondary endpoints, and Telor has decided to drop the product from development.
Ethacrynate has had a troubled development at Telor. In 1993, another formulation of the drug, called Tekron, had to be reformulated after Phase IIa trial results suggested that the product was associated with an unacceptable degree of ocular irritation, and this product was pulled from development in November of last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze